Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission

Erica D. Warlick, Kristjan Paulson, Ruta Brazauskas, Xiaobo Zhong, Alan M. Miller, Bruce M. Camitta, Biju George, Bipin N. Savani, Celalettin Ustun, David I. Marks, Edmund K. Waller, Frédéric Baron, César O. Freytes, Gérard Socie, Gorgun Akpek, Harry C. Schouten, Hillard M. Lazarus, Edwin M. Horwitz, John Koreth, Jean Yves CahnMartin Bornhauser, Matthew Seftel, Mitchell S. Cairo, Mary J. Laughlin, Mitchell Sabloff, Olle Ringdén, Robert Peter Gale, Rammurti T. Kamble, Ravi Vij, Usama Gergis, Vikram Mathews, Wael Saber, Yi Bin Chen, Jane L. Liesveld, Corey S. Cutler, Armin Ghobadi, Geoffrey L. Uy, Mary Eapen, Daniel J. Weisdorf, Mark R Litzow

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The impact of pretransplant (hematopoietic cell transplantation [HCT]) cytarabine consolidation therapy on post-HCT outcomes has yet to be evaluated after reduced-intensity or nonmyeloablative conditioning. We analyzed 604 adults with acute myeloid leukemia in first complete remission (CR1) reported to the Center for International Blood and Marrow Transplant Research who received a reduced-intensity or nonmyeloablative conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, or umbilical cord blood donor from 2000 to 2010. We compared transplant outcomes based on exposure to cytarabine postremission consolidation. Three-year survival rates were 36% (95% confidence interval [CI], 29% to 43%) in the no consolidation arm and 42% (95% CI, 37% to 47%) in the cytarabine consolidation arm (P= 16). Disease-free survival was 34% (95% CI, 27% to 41%) and 41% (95% CI, 35% to 46%; P= 15), respectively. Three-year cumulative incidences of relapse were 37% (95% CI, 30% to 44%) and 38% (95% CI, 33% to 43%), respectively (P= 80). Multivariate regression confirmed no effect of consolidation on relapse, disease-free survival, and survival. Before reduced-intensity or nonmyeloablative conditioning HCT, these data suggest pre-HCT consolidation cytarabine does not significantly alter outcomes and support prompt transition to transplant as soon as morphologic CR1 is attained. If HCT is delayed while identifying a donor, our data suggest that consolidation does not increase transplant treatment-related mortality and is reasonable if required.

Original languageEnglish (US)
Pages (from-to)202-208
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Cell Transplantation
Homologous Transplantation
Acute Myeloid Leukemia
Cytarabine
Confidence Intervals
Transplants
Disease-Free Survival
Arm
Therapeutics
Recurrence
Unrelated Donors
Blood Donors
Fetal Blood
Conditioning (Psychology)
Siblings
Survival Rate
Bone Marrow
Tissue Donors
Survival
Mortality

Keywords

  • AML
  • Cytarabine consolidation
  • RIC

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. / Warlick, Erica D.; Paulson, Kristjan; Brazauskas, Ruta; Zhong, Xiaobo; Miller, Alan M.; Camitta, Bruce M.; George, Biju; Savani, Bipin N.; Ustun, Celalettin; Marks, David I.; Waller, Edmund K.; Baron, Frédéric; Freytes, César O.; Socie, Gérard; Akpek, Gorgun; Schouten, Harry C.; Lazarus, Hillard M.; Horwitz, Edwin M.; Koreth, John; Cahn, Jean Yves; Bornhauser, Martin; Seftel, Matthew; Cairo, Mitchell S.; Laughlin, Mary J.; Sabloff, Mitchell; Ringdén, Olle; Gale, Robert Peter; Kamble, Rammurti T.; Vij, Ravi; Gergis, Usama; Mathews, Vikram; Saber, Wael; Chen, Yi Bin; Liesveld, Jane L.; Cutler, Corey S.; Ghobadi, Armin; Uy, Geoffrey L.; Eapen, Mary; Weisdorf, Daniel J.; Litzow, Mark R.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 2, 02.2014, p. 202-208.

Research output: Contribution to journalArticle

Warlick, ED, Paulson, K, Brazauskas, R, Zhong, X, Miller, AM, Camitta, BM, George, B, Savani, BN, Ustun, C, Marks, DI, Waller, EK, Baron, F, Freytes, CO, Socie, G, Akpek, G, Schouten, HC, Lazarus, HM, Horwitz, EM, Koreth, J, Cahn, JY, Bornhauser, M, Seftel, M, Cairo, MS, Laughlin, MJ, Sabloff, M, Ringdén, O, Gale, RP, Kamble, RT, Vij, R, Gergis, U, Mathews, V, Saber, W, Chen, YB, Liesveld, JL, Cutler, CS, Ghobadi, A, Uy, GL, Eapen, M, Weisdorf, DJ & Litzow, MR 2014, 'Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission', Biology of Blood and Marrow Transplantation, vol. 20, no. 2, pp. 202-208. https://doi.org/10.1016/j.bbmt.2013.10.023
Warlick, Erica D. ; Paulson, Kristjan ; Brazauskas, Ruta ; Zhong, Xiaobo ; Miller, Alan M. ; Camitta, Bruce M. ; George, Biju ; Savani, Bipin N. ; Ustun, Celalettin ; Marks, David I. ; Waller, Edmund K. ; Baron, Frédéric ; Freytes, César O. ; Socie, Gérard ; Akpek, Gorgun ; Schouten, Harry C. ; Lazarus, Hillard M. ; Horwitz, Edwin M. ; Koreth, John ; Cahn, Jean Yves ; Bornhauser, Martin ; Seftel, Matthew ; Cairo, Mitchell S. ; Laughlin, Mary J. ; Sabloff, Mitchell ; Ringdén, Olle ; Gale, Robert Peter ; Kamble, Rammurti T. ; Vij, Ravi ; Gergis, Usama ; Mathews, Vikram ; Saber, Wael ; Chen, Yi Bin ; Liesveld, Jane L. ; Cutler, Corey S. ; Ghobadi, Armin ; Uy, Geoffrey L. ; Eapen, Mary ; Weisdorf, Daniel J. ; Litzow, Mark R. / Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 2. pp. 202-208.
@article{6b910afd1d5141eda55e7da3889b0175,
title = "Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission",
abstract = "The impact of pretransplant (hematopoietic cell transplantation [HCT]) cytarabine consolidation therapy on post-HCT outcomes has yet to be evaluated after reduced-intensity or nonmyeloablative conditioning. We analyzed 604 adults with acute myeloid leukemia in first complete remission (CR1) reported to the Center for International Blood and Marrow Transplant Research who received a reduced-intensity or nonmyeloablative conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, or umbilical cord blood donor from 2000 to 2010. We compared transplant outcomes based on exposure to cytarabine postremission consolidation. Three-year survival rates were 36{\%} (95{\%} confidence interval [CI], 29{\%} to 43{\%}) in the no consolidation arm and 42{\%} (95{\%} CI, 37{\%} to 47{\%}) in the cytarabine consolidation arm (P= 16). Disease-free survival was 34{\%} (95{\%} CI, 27{\%} to 41{\%}) and 41{\%} (95{\%} CI, 35{\%} to 46{\%}; P= 15), respectively. Three-year cumulative incidences of relapse were 37{\%} (95{\%} CI, 30{\%} to 44{\%}) and 38{\%} (95{\%} CI, 33{\%} to 43{\%}), respectively (P= 80). Multivariate regression confirmed no effect of consolidation on relapse, disease-free survival, and survival. Before reduced-intensity or nonmyeloablative conditioning HCT, these data suggest pre-HCT consolidation cytarabine does not significantly alter outcomes and support prompt transition to transplant as soon as morphologic CR1 is attained. If HCT is delayed while identifying a donor, our data suggest that consolidation does not increase transplant treatment-related mortality and is reasonable if required.",
keywords = "AML, Cytarabine consolidation, RIC",
author = "Warlick, {Erica D.} and Kristjan Paulson and Ruta Brazauskas and Xiaobo Zhong and Miller, {Alan M.} and Camitta, {Bruce M.} and Biju George and Savani, {Bipin N.} and Celalettin Ustun and Marks, {David I.} and Waller, {Edmund K.} and Fr{\'e}d{\'e}ric Baron and Freytes, {C{\'e}sar O.} and G{\'e}rard Socie and Gorgun Akpek and Schouten, {Harry C.} and Lazarus, {Hillard M.} and Horwitz, {Edwin M.} and John Koreth and Cahn, {Jean Yves} and Martin Bornhauser and Matthew Seftel and Cairo, {Mitchell S.} and Laughlin, {Mary J.} and Mitchell Sabloff and Olle Ringd{\'e}n and Gale, {Robert Peter} and Kamble, {Rammurti T.} and Ravi Vij and Usama Gergis and Vikram Mathews and Wael Saber and Chen, {Yi Bin} and Liesveld, {Jane L.} and Cutler, {Corey S.} and Armin Ghobadi and Uy, {Geoffrey L.} and Mary Eapen and Weisdorf, {Daniel J.} and Litzow, {Mark R}",
year = "2014",
month = "2",
doi = "10.1016/j.bbmt.2013.10.023",
language = "English (US)",
volume = "20",
pages = "202--208",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission

AU - Warlick, Erica D.

AU - Paulson, Kristjan

AU - Brazauskas, Ruta

AU - Zhong, Xiaobo

AU - Miller, Alan M.

AU - Camitta, Bruce M.

AU - George, Biju

AU - Savani, Bipin N.

AU - Ustun, Celalettin

AU - Marks, David I.

AU - Waller, Edmund K.

AU - Baron, Frédéric

AU - Freytes, César O.

AU - Socie, Gérard

AU - Akpek, Gorgun

AU - Schouten, Harry C.

AU - Lazarus, Hillard M.

AU - Horwitz, Edwin M.

AU - Koreth, John

AU - Cahn, Jean Yves

AU - Bornhauser, Martin

AU - Seftel, Matthew

AU - Cairo, Mitchell S.

AU - Laughlin, Mary J.

AU - Sabloff, Mitchell

AU - Ringdén, Olle

AU - Gale, Robert Peter

AU - Kamble, Rammurti T.

AU - Vij, Ravi

AU - Gergis, Usama

AU - Mathews, Vikram

AU - Saber, Wael

AU - Chen, Yi Bin

AU - Liesveld, Jane L.

AU - Cutler, Corey S.

AU - Ghobadi, Armin

AU - Uy, Geoffrey L.

AU - Eapen, Mary

AU - Weisdorf, Daniel J.

AU - Litzow, Mark R

PY - 2014/2

Y1 - 2014/2

N2 - The impact of pretransplant (hematopoietic cell transplantation [HCT]) cytarabine consolidation therapy on post-HCT outcomes has yet to be evaluated after reduced-intensity or nonmyeloablative conditioning. We analyzed 604 adults with acute myeloid leukemia in first complete remission (CR1) reported to the Center for International Blood and Marrow Transplant Research who received a reduced-intensity or nonmyeloablative conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, or umbilical cord blood donor from 2000 to 2010. We compared transplant outcomes based on exposure to cytarabine postremission consolidation. Three-year survival rates were 36% (95% confidence interval [CI], 29% to 43%) in the no consolidation arm and 42% (95% CI, 37% to 47%) in the cytarabine consolidation arm (P= 16). Disease-free survival was 34% (95% CI, 27% to 41%) and 41% (95% CI, 35% to 46%; P= 15), respectively. Three-year cumulative incidences of relapse were 37% (95% CI, 30% to 44%) and 38% (95% CI, 33% to 43%), respectively (P= 80). Multivariate regression confirmed no effect of consolidation on relapse, disease-free survival, and survival. Before reduced-intensity or nonmyeloablative conditioning HCT, these data suggest pre-HCT consolidation cytarabine does not significantly alter outcomes and support prompt transition to transplant as soon as morphologic CR1 is attained. If HCT is delayed while identifying a donor, our data suggest that consolidation does not increase transplant treatment-related mortality and is reasonable if required.

AB - The impact of pretransplant (hematopoietic cell transplantation [HCT]) cytarabine consolidation therapy on post-HCT outcomes has yet to be evaluated after reduced-intensity or nonmyeloablative conditioning. We analyzed 604 adults with acute myeloid leukemia in first complete remission (CR1) reported to the Center for International Blood and Marrow Transplant Research who received a reduced-intensity or nonmyeloablative conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, or umbilical cord blood donor from 2000 to 2010. We compared transplant outcomes based on exposure to cytarabine postremission consolidation. Three-year survival rates were 36% (95% confidence interval [CI], 29% to 43%) in the no consolidation arm and 42% (95% CI, 37% to 47%) in the cytarabine consolidation arm (P= 16). Disease-free survival was 34% (95% CI, 27% to 41%) and 41% (95% CI, 35% to 46%; P= 15), respectively. Three-year cumulative incidences of relapse were 37% (95% CI, 30% to 44%) and 38% (95% CI, 33% to 43%), respectively (P= 80). Multivariate regression confirmed no effect of consolidation on relapse, disease-free survival, and survival. Before reduced-intensity or nonmyeloablative conditioning HCT, these data suggest pre-HCT consolidation cytarabine does not significantly alter outcomes and support prompt transition to transplant as soon as morphologic CR1 is attained. If HCT is delayed while identifying a donor, our data suggest that consolidation does not increase transplant treatment-related mortality and is reasonable if required.

KW - AML

KW - Cytarabine consolidation

KW - RIC

UR - http://www.scopus.com/inward/record.url?scp=84893149821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893149821&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.10.023

DO - 10.1016/j.bbmt.2013.10.023

M3 - Article

C2 - 24184335

AN - SCOPUS:84893149821

VL - 20

SP - 202

EP - 208

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -